Emma Asma Cornwall
0
All posts from Emma Asma Cornwall
Emma Asma Cornwall in Gainers & Losers,

Isis Pharmaceuticals is short-term "buy"

Isis Pharmaceuticals (don't confuse with, you know) started an open-label extension study, that will provide ISIS-SMNrx to infants and children with spinal muscular atrophy (SMA) who completed their participation in the Phase 3 ENDEAR and CHERISH studies. ENDEAR graduates will receive a 12 mg dose of ISIS-SMNrx every four months while CHERISH graduates will receive a 12 mg dose every six months.

The initiation of study triggers an $11M milestone payment from co-developer Biogen. Good news for Isis!

Technical condition of the stock is constructive, too. Short-term buy!